Tannic acid
Depinar (tannic acid) is an unknown pharmaceutical. Tannic acid was first approved as Depinar on 1982-01-01. It is known to target anoctamin-1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cyanocobalamin
+
Tannic acid
+
Zinc acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEPINAR | Armour Pharmaceutical | N-011208 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nitrotan | OTC monograph not final | 2013-07-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
6074 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 9 | 6 | 8 | 13 | 176 | 210 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 11 | 6 | 10 | 11 | 122 | 156 |
| Syndrome | D013577 | — | — | 10 | 23 | 19 | 10 | 92 | 147 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 8 | 4 | 14 | 16 | 86 | 128 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 8 | 11 | 6 | 94 | 118 |
| Cognitive dysfunction | D060825 | — | G31.84 | 5 | 12 | 5 | 6 | 78 | 103 |
| Depression | D003863 | — | F33.9 | 6 | 2 | 6 | 2 | 87 | 103 |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 6 | 10 | 11 | 72 | 99 |
| Respiratory insufficiency | D012131 | — | J96.9 | 1 | 8 | 8 | 3 | 72 | 91 |
| Overweight | D050177 | — | E66.3 | 2 | 3 | 3 | 2 | 81 | 90 |
Show 441 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | 1 | 2 | — | 103 | 106 |
| Covid-19 | D000086382 | — | U07.1 | — | 10 | 10 | — | 45 | 64 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | 2 | 1 | 1 | — | 43 | 47 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | 1 | 1 | — | 41 | 43 |
| Anxiety | D001007 | EFO_0005230 | F41.1 | 3 | 2 | 1 | — | 36 | 41 |
| Obstructive lung diseases | D008173 | — | — | — | 4 | 2 | — | 31 | 37 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 2 | 2 | 3 | — | 30 | 37 |
| Sclerosis | D012598 | — | — | 2 | 7 | 3 | — | 25 | 35 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | 1 | — | 31 | 32 |
| Premature birth | D047928 | EFO_0003917 | O60 | 1 | 1 | 1 | — | 28 | 30 |
Show 305 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aging | D000375 | GO_0007568 | R41.81 | 3 | 3 | — | — | 49 | 55 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | 1 | — | — | 47 | 48 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 3 | 2 | — | — | 38 | 43 |
| Neck pain | D019547 | — | M54.2 | — | 1 | — | — | 39 | 40 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 3 | 3 | — | — | 28 | 34 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 4 | 3 | — | — | 19 | 25 |
| Sleep wake disorders | D012893 | — | G47 | 3 | 1 | — | — | 20 | 24 |
| Pediatric obesity | D063766 | — | — | — | 1 | — | — | 22 | 23 |
| Dyspnea | D004417 | — | R06.0 | — | 1 | — | — | 16 | 17 |
| Parasomnias | D020447 | — | G47.5 | 3 | 1 | — | — | 12 | 16 |
Show 287 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral palsy | D002547 | — | G80 | 3 | — | — | — | 28 | 31 |
| Sleep | D012890 | GO_0030431 | — | 4 | — | — | — | 20 | 24 |
| Pain management | D059408 | — | — | 2 | — | — | — | 10 | 12 |
| Mental health | D008603 | EFO_0003935 | — | 1 | — | — | — | 11 | 12 |
| Healthy diet | D000072001 | — | — | 1 | — | — | — | 10 | 11 |
| Laparoscopic cholecystectomy | D017081 | — | — | 2 | — | — | — | 7 | 9 |
| Problem behavior | D000066553 | — | — | 1 | — | — | — | 8 | 9 |
| Oxygen inhalation therapy | D010102 | — | — | 1 | — | — | — | 8 | 9 |
| Hyperthermia | D000084462 | — | — | 1 | — | — | — | 8 | 9 |
| Respiration disorders | D012120 | — | J00-J99 | 1 | — | — | — | 7 | 8 |
Show 51 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sedentary behavior | D057185 | — | — | — | — | — | — | 57 | 57 |
| Chronic pain | D059350 | — | — | — | — | — | — | 30 | 30 |
| Emergencies | D004630 | — | — | — | — | — | — | 20 | 20 |
| Health behavior | D015438 | — | — | — | — | — | — | 20 | 20 |
| Psychological stress | D013315 | — | — | — | — | — | — | 15 | 15 |
| Dental caries | D003731 | EFO_0003819 | K02 | — | — | — | — | 15 | 15 |
| Scoliosis | D012600 | EFO_0004273 | M41 | — | — | — | — | 14 | 14 |
| Disease progression | D018450 | — | — | — | — | — | — | 13 | 13 |
| Weight gain | D015430 | — | — | — | — | — | — | 13 | 13 |
| Feeding behavior | D005247 | — | — | — | — | — | — | 13 | 13 |
Show 1011 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tannic acid |
| INN | _ |
| Description | Tannic acid is a specific form of tannin, a type of polyphenol. Its weak acidity (pKa around 6) is due to the numerous phenol groups in the structure. The chemical formula for commercial tannic acid is often given as C76H52O46, which corresponds with decagalloyl glucose, but in fact it is a mixture of polygalloyl glucoses or polygalloyl quinic acid esters with the number of galloyl moieties per molecule ranging from 2 up to 12 depending on the plant source used to extract the tannic acid. Commercial tannic acid is usually extracted from any of the following plant parts: Tara pods (Caesalpinia spinosa), gallnuts from Rhus semialata or Quercus infectoria or Sicilian sumac leaves (Rhus coriaria).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1401-55-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL506247 |
| ChEBI ID | 81066 |
| PubChem CID | 16129778 |
| DrugBank | — |
| UNII ID | 28F9E0DJY6 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ANO1
ANO1
Organism
Homo sapiens
Gene name
ANO1
Gene synonyms
DOG1, ORAOV2, TAOS2, TMEM16A
NCBI Gene ID
Protein name
anoctamin-1
Protein synonyms
anoctamin 1, calcium activated chloride channel, Ca2+-activated Cl- channel, calcium activated chloride channel, Discovered on gastrointestinal stromal tumors protein 1, oral cancer overexpressed 2, Oral cancer overexpressed protein 2, Transmembrane protein 16A, transmembrane protein 16A (eight membrane-spanning domains), Tumor-amplified and overexpressed sequence 2
Uniprot ID
Mouse ortholog
Ano1 (101772)
anoctamin-1 (Q99JK1)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,455 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use